These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8091742)

  • 41. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Distribution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate.
    Hart H; Jones A; Cubie H; McIntosh RV; Cuthbertson B
    Vox Sang; 1994; 67 Suppl 1():51-5. PubMed ID: 8091738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation.
    Raut S; Di Giambattista M; Bevan SA; Hubbard AR; Barrowcliffe TW; Laub R
    Thromb Haemost; 1998 Oct; 80(4):624-31. PubMed ID: 9798982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
    Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
    Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of hepatitis A in Dutch hemophilia patients.
    Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; van den Berg HM; Roosendaal G; Lelie PN
    Thromb Haemost; 1995 Aug; 74(2):616-8. PubMed ID: 8584994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transmission of hepatitis A by transfusion of blood products.
    Sherertz RJ; Russell BA; Reuman PD
    Arch Intern Med; 1984 Aug; 144(8):1579-80. PubMed ID: 6087755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus.
    Gowland P; Fontana S; Niederhauser C; Taleghani BM
    Transfusion; 2004 Nov; 44(11):1555-61. PubMed ID: 15504159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
    Austen DE; Smith JK
    Thromb Haemost; 1982 Aug; 48(1):46-8. PubMed ID: 6813994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human parvovirus PARV4 in clotting factor VIII concentrates.
    Fryer JF; Hubbard AR; Baylis SA
    Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An investigation of hepatitis A virus infected blood products.
    Seal LA; Lerud KS; Riel MA; Hill RB; Nadala C
    Mil Med; 1990 Jun; 155(6):241-3. PubMed ID: 2172868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. H5N1 influenza virus and the safety of plasma products.
    Kreil TR; Unger U; Orth SM; Petutschnig G; Kistner O; Poelsler G; Berting A
    Transfusion; 2007 Mar; 47(3):452-9. PubMed ID: 17319825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products.
    Unger U; Poelsler G; Modrof J; Kreil TR
    Transfusion; 2009 Sep; 49(9):1924-30. PubMed ID: 19453977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clearance of dengue virus in the plasma-derived therapeutic proteins.
    Xie YW; Chan PK; Szeto CK; Kwok SY; Chu IM; Chu SS; Cheung JL; Wong SW; Ali MB; Wong BL
    Transfusion; 2008 Jul; 48(7):1342-7. PubMed ID: 18315529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis A viral safety of plasma-derived factor VIII concentrate Koate-HP.
    Mitra G; Dobkin M; Dumas M; Ng P; Roldan G; Galloway C
    Vox Sang; 1994; 67 Suppl 1():80-2. PubMed ID: 8091744
    [No Abstract]   [Full Text] [Related]  

  • 60. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
    Roberts P
    Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.